PD-1 × VEGF bispecifics after ivonescimab
A bispecific has three pharmacological edges over a two-drug combo: higher local concentration in the tumor; VEGF is itself an immune suppressor, so blocking it also frees dendritic cells and T-cell entry; vessel normalization lets T cells in.
Most molecules hit PD-1 × VEGF; BioNTech’s BNT327 / pumitamig hits PD-L1 × VEGF-A.
#AACR26 Junshi reports PD‑1×VEGF + CTLA‑4 combo in HCC
a Phase II data for JS207 (PD‑1 × VEGF‑A bispecific) combined with JS007 (anti‑CTLA‑4) as 1L therapy in advanced hepatocellular carcinoma.
https://
aacrjournals.org/cancerres/arti
cle/86/8_Supplement/CT159/782900/Abstract-CT159-JS207-a-bispecific-antibody?searchresult=1
…
• High early efficacy signal in a difficult tumor: ORR
Heat 30 · 25 likes · 0 replies · 5 reposts
Yong Gao, Zhiwei Li, Jianwei Yang, Shuqing Jin, Yiyi Yu, Chang Wang, Xiwen Huang, Jingdong Zhang, Yanhong Gu, Shuqin Ni, Yanlai Sun, Shirong Cai, Liang Han, Xinjun Liang, Haichuan Su, Chenxi Wang, Zhenyu Xu, Jing Xu, Chengbo Jia, Jianjun Zou, Lin Shen
Read the abstract →Jian Zhou, Guoming Shi, Yongsheng Ge, Shuijun Zhang, Xiwen Huang, Shunda Du, Yong Gao, Guohong Han, Xiaoyong Huang, Zhenda Wang, Junliang Li, Jing Xu, Jiazheng Yan, Jianjun Zou, Jia Fan
Read the abstract →Source: Minhua Chu · x.com